Thus, the combination of CA125 and HE4 measurements could be used for a more efficient prediction of ovarian cancer as well as for monitoring the therapy efficiency in ovarian cancer patients [23,29]. This evidence concerns the gene WFDC2 and ovarian carcinoma.